CN101658669A - 减毒的活疫苗 - Google Patents

减毒的活疫苗 Download PDF

Info

Publication number
CN101658669A
CN101658669A CN200910142709A CN200910142709A CN101658669A CN 101658669 A CN101658669 A CN 101658669A CN 200910142709 A CN200910142709 A CN 200910142709A CN 200910142709 A CN200910142709 A CN 200910142709A CN 101658669 A CN101658669 A CN 101658669A
Authority
CN
China
Prior art keywords
virus
gly
lys
leu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910142709A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗兹·X·海因茨
克里斯琴·曼德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3670551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101658669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of CN101658669A publication Critical patent/CN101658669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200910142709A 2001-02-21 2002-02-11 减毒的活疫苗 Pending CN101658669A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA272/2001 2001-02-21
AT0027201A AT410634B (de) 2001-02-21 2001-02-21 Attenuierte lebendimpfstoffe

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA02805217XA Division CN1492923A (zh) 2001-02-21 2002-02-11 减毒的活疫苗

Publications (1)

Publication Number Publication Date
CN101658669A true CN101658669A (zh) 2010-03-03

Family

ID=3670551

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200910142709A Pending CN101658669A (zh) 2001-02-21 2002-02-11 减毒的活疫苗
CN200810149940A Pending CN101670101A (zh) 2001-02-21 2002-02-11 减毒的活疫苗
CNA02805217XA Pending CN1492923A (zh) 2001-02-21 2002-02-11 减毒的活疫苗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN200810149940A Pending CN101670101A (zh) 2001-02-21 2002-02-11 减毒的活疫苗
CNA02805217XA Pending CN1492923A (zh) 2001-02-21 2002-02-11 减毒的活疫苗

Country Status (10)

Country Link
US (2) US8486419B2 (ko)
EP (1) EP1373478B1 (ko)
JP (2) JP5091385B2 (ko)
KR (1) KR100850620B1 (ko)
CN (3) CN101658669A (ko)
AT (2) AT410634B (ko)
AU (1) AU2002229390B2 (ko)
CA (1) CA2432370C (ko)
DE (1) DE50206472D1 (ko)
WO (1) WO2002066621A1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
AU2003258611A1 (en) * 2002-08-13 2004-03-03 Akzo Nobel N.V. Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
WO2005040390A1 (fr) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
CA2582534A1 (en) * 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1896069B1 (en) 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
HUE031617T2 (en) * 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and preparations for live attenuated viruses
WO2009098277A1 (en) 2008-02-08 2009-08-13 Intercell Ag Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
CN102488893B (zh) * 2011-12-28 2013-07-17 瑞普（保定）生物药业有限公司 一种用细胞系生产鸭出血性卵巢炎灭活疫苗的方法及其制品
JP2015524421A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
SG11201500439RA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
CN103143008B (zh) * 2013-03-07 2014-04-09 齐鲁动物保健品有限公司 一种鸭坦布苏病毒活疫苗及其制备方法
EP3355916A4 (en) * 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
CN113215117B (zh) * 2021-05-17 2022-09-06 四川农业大学 一种鸭坦布苏病毒致弱活疫苗候选株及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
ES2254055T3 (es) * 1991-09-19 2006-06-16 The United States Of America, As Represented By The Secretary, Departm. Of Health And Human Services Flavivirus quimericos y/o de crecimiento restringido.
FR2690921B1 (fr) * 1992-05-06 1995-06-30 Bio Merieux Polypeptides de synthese appartenant au virus de l'hepatite c (vhc) et utilisables notamment pour detecter ce dernier.
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2760367B1 (fr) * 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
AU2003258611A1 (en) * 2002-08-13 2004-03-03 Akzo Nobel N.V. Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
WO2009098277A1 (en) 2008-02-08 2009-08-13 Intercell Ag Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines

Also Published As

Publication number Publication date
ATE323758T1 (de) 2006-05-15
EP1373478B1 (de) 2006-04-19
US20040052818A1 (en) 2004-03-18
CA2432370C (en) 2012-01-31
US20110165230A1 (en) 2011-07-07
AU2002229390B2 (en) 2006-03-16
JP2004520406A (ja) 2004-07-08
WO2002066621A1 (de) 2002-08-29
EP1373478A1 (de) 2004-01-02
CA2432370A1 (en) 2002-08-29
CN101670101A (zh) 2010-03-17
ATA2722001A (de) 2002-11-15
KR20030081457A (ko) 2003-10-17
KR100850620B1 (ko) 2008-08-05
DE50206472D1 (de) 2006-05-24
US8784839B2 (en) 2014-07-22
US8486419B2 (en) 2013-07-16
JP5091385B2 (ja) 2012-12-05
CN1492923A (zh) 2004-04-28
AT410634B (de) 2003-06-25
JP2010132686A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
CN101658669A (zh) 减毒的活疫苗
US20200392469A1 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
US20240084269A1 (en) Development of dengue virus vaccine components
US10869920B2 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
EP1605047A1 (en) Chimeric and/or growth-restricted flaviviruses
US7507415B2 (en) West nile virus vaccine
KR20180137514A (ko) 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
TW201516147A (zh) 用於疫苗中之登革熱病毒嵌合式建構物的組成物及方法
US20190194260A1 (en) Live attenuated zika virus vaccine
JP4871738B2 (ja) 弱毒日本脳炎ウイルスの遺伝子をバックボーンとして有する弱毒キメラフラビウイルス
CA3091508A1 (en) Attenuated flaviviruses
US11123420B2 (en) Stable live attenuated recombinant dengue vaccine
AU2021202950B2 (en) Development of dengue virus vaccine components
AU2017203108B2 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100303